Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation (ECIT-1)

This study has been completed.
Sponsor:
Collaborator:
Juvenile Diabetes Research Foundation
Information provided by (Responsible Party):
Piemonti Lorenzo, Ospedale San Raffaele
ClinicalTrials.gov Identifier:
NCT01346085
First received: April 29, 2011
Last updated: April 9, 2014
Last verified: April 2014

April 29, 2011
April 9, 2014
October 2006
June 2009   (final data collection date for primary outcome measure)
The Proportion of Insulin Free Patients 3 Years After the Last Islet Infusion [ Time Frame: 3 year ] [ Designated as safety issue: No ]
Insulin independence is defined as no need for exogenous insulin, with adequate glycemic control [i.e., glycated hemoglobin <7% (normal range 3.5 - 6.0%), fasting glucose levels not exceeding 140 mg/dL (7.8 mmol/L) more than three times per week and 2-hour postprandial levels not exceeding 180 mg/dL (10 mmol/L) more than four times per week].
the proportion of insulin free patients one and two years after the 1st islet infusion [ Time Frame: years 1 and 2 ] [ Designated as safety issue: No ]
Insulin independence is defined as no need for exogenous insulin, with adequate glycemic control [i.e., glycated hemoglobin <6.5% (normal range 3.5 - 6.0%), fasting glucose levels not exceeding 140 mg/dL (7.8 mmol/L) more than three times per week and 2-hour postprandial levels not exceeding 180 mg/dL (10 mmol/L) more than four times per week].
Complete list of historical versions of study NCT01346085 on ClinicalTrials.gov Archive Site
  • Insulin Independence With Adequate Glycemic Control Throughout Follow-up [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
  • Glycated Hemoglobin Levels Throughout Follow-up [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
  • Basal and Stimulated Blood C-peptide Levels in Response to Arginine Challenge Throughout Follow-up [ Time Frame: up to 3 year ] [ Designated as safety issue: No ]
  • the Reduction in Insulin Requirement Compared to Baseline [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
  • Severe Hypoglycemic Events Since Completion of Transplant [ Time Frame: up to 3 years ] [ Designated as safety issue: Yes ]
  • Any Adverse Event Throughout Follow-up [ Time Frame: up to 3 years ] [ Designated as safety issue: Yes ]
    Among study participants there were no reports of death, post-transplantation lymphoproliferative disease, cancer, or opportunistic infections. There was no evidence of cytomegalovirus disease, infection or serological activation (CMV early antigens negative during the whole follow-up), nor of Epstein-Barr clinical and serological reactivation (all patients were antibodies anti EBV positive before transplant, as per the inclusion criteria).
  • insulin independence with adequate glycemic control throughout follow-up [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
  • glycated hemoglobin levels throughout follow-up [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
  • basal and stimulated blood C-peptide levels in response to arginine challenge throughout follow-up [ Time Frame: up to 3 year ] [ Designated as safety issue: No ]
  • the reduction in insulin requirement compared to baseline [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
  • severe hypoglycemic events since completion of transplant [ Time Frame: up to 3 years ] [ Designated as safety issue: Yes ]
  • Any adverse event throughout follow-up [ Time Frame: up to 3 years ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation
A Multi-step Trial Towards Single Donor Islet Transplantation in Type 1 Diabetic Patients, Using Calcineurin Inhibitor-free Immunosuppression

Our final objective is to develop an adoptive therapy with tolerogenic donor-specific Tr1 cells in T1D patients undergoing pancreatic islet transplantation (Tx). The achievement of this objective depends by the availability of an immunosuppressive treatment (IS) compatible with the survival, function, and expansion of the transferred Tr1 cells. For this purpose the investigators design a CNI-free single-group, phase 1-2 trial excluding the ATG or anti-CD25 induction therapy after the 1st islet infusion

We designed the clinical trial as a single-arm, phase 1-2 trial conducted in two transplant centers (San Raffaele Scientific Institute, Milan, Italy; Cell Isolation and Transplantation Center, University of Geneva, Geneva, Switzerland) which used a common protocol for islet preparation, post-transplantation patient management and data collection. The trial is exploratory in nature and the target enrollment is 10 patients. The recruitment is competitive between the two centers and each patient is to receive at least 10,000 IE/kg. Up to three islet infusions are allowed per patients until insulin independence is reached, provided that partial islet function (i.e., fasting C-peptide ≥0.3 ng/mL) is maintained between infusions. We planned an individual follow-up of 3 years after the last islet infusion.

Patients with type 1 diabetes are eligible for this study. Major criteria for inclusion are: age 18-65 years; type 1 diabetes with onset <40 years of age; insulin treatment of at least 5 years at the time of enrollment; stimulated C-peptide in response to arginine <0.5 ng/ml; multiple (three or more) daily insulin injections or Continuous Subcutaneous Insulin Infusion; self-blood glucose monitoring ≥3 times/day; high glycemic instability and/or hypoglycemia unawareness; inability to consistently attain a glycated hemoglobin target of <7.5 % without severe hypoglycemia (defined as an hypoglycemic episode requiring the assistance by another person for its resolution) in the past 36 months despite medical management by a diabetes specialist. Major criteria for exclusion are: HbA1c >12%; BMI >30 kg/m2, or insulin requirement > 0.8 IU/kg/day; poorly controlled hypertension; untreated proliferative diabetic retinopathy; presence or history of macroalbuminuria (>300mg/g day) or estimated glomerular filtration rate <60 ml/min/1.73 m2 for females or <70 ml/min/1.73 m2 for males.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Type 1 Diabetes
Drug: CNI free immunosuppression
Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).
Other Name: Kineret, Rapamune, Thymoglobulin, Myfortic
Experimental: CNI-free single-group
Intervention: Drug: CNI free immunosuppression

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
June 2012
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female patients aged 18-65yr
  • ability to provide written informed consent and comply with the study protocol procedures
  • clinical history of type 1 diabetes with onset <40yr of age, on insulin for at least 5yr at the time of enrollment
  • absent stimulated C-peptide (<0.5ng/ml) in response to arginine
  • multiple (three or more) daily insulin injections or insulin pump therapy
  • self blood glucose monitoring ≥3 times/day, supervised by a specialist physician
  • high glycemic instability and hypoglycemia unawareness
  • inability to consistently attain a HbA1c < 7.5 % target without experiencing severe hypoglycemia (assistance by another person) in the past 36 months despite appropriate medical management.

Exclusion Criteria:

  • HbA1c >12%
  • BMI >30 kg/m2, or insulin requirement of > 0.8 IU/kg/day;
  • poorly controlled hypertension;
  • untreated proliferative diabetic retinopathy;
  • presence or history of macroalbuminuria (>300mg/g day) or measured glomerular filtration rate <60 ml/min/1.73 m2 for females and <70 ml/min/1.73 m2 for males
  • for female participants: positive pregnancy test, presently breast-feeding, or unwilling to use effective contraceptive measures for the duration of the study and 3 months after discontinuation
  • for male participants: intent to procreate during the duration of the study or within 3 months after discontinuation or unwillingness to use effective measures of contraception;
  • any history of malignancy within the previous 5 years, except for completely resected squamous or basal cell carcinoma of the skin;
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Italy,   Switzerland
 
NCT01346085
ECIT-1
Yes
Piemonti Lorenzo, Ospedale San Raffaele
Ospedale San Raffaele
Juvenile Diabetes Research Foundation
Principal Investigator: Lorenzo Piemonti, MD Fondazione Centro San Raffaele del Monte Tabor
Principal Investigator: Thierry Berney, MD Universitè de Geneve
Study Chair: Antonio Secchi, MD Fondazione Centro San Raffaele del Monte Tabor
Study Director: Paola Maffi, MD Cantro San Raffaele del Monte Tabor
Ospedale San Raffaele
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP